Longitudinal lipid profile variations and clinical change in Alzheimer's disease dementia
de Oliveira, Fabricio Ferreira [UNIFESP]
Chen, Elizabeth Suchi [UNIFESP]
Smith, Marilia Cardoso [UNIFESP]
Ferreira Bertolucci, Paulo Henrique [UNIFESP]
Is part ofNeuroscience Letters
MetadataShow full item record
Hypercholesterolemia and statin use have been unevenly associated with clinical change in Alzheimer's disease dementia. In this longitudinal study, 192 consecutive outpatients with late-onset Alzheimer's disease dementia were stratified according to APOE haplotypes, and followed for one year to investigate associations of lipid profile variations and lipophilic statin therapy with changes in cognition, caregiver burden, basic and instrumental functionality. Overall, 102 patients (53.1%) carried APOE4+ haplotypes and 90 (46.9%) carried APOE4- haplotypes189 patients (98.4%) used either a cholinesterase inhibitor, or Memantine, or both144 patients had dyslipidemias and 143 of them received statin therapy. Total cholesterol, LDL-cholesterol, Mini-Mental State Examination scores, and functional independence scores were significantly lower at the end of the follow-up, while Clinical Dementia Rating sum-of-boxes scores were higher. Exclusively for APOE4- carriers, rising LDL-cholesterol levels were associated with a trend toward improvements in the Index of Independence in Activities of Daily Living (beta=0.010rho= 0.16), whereas rising HDL-cholesterol levels were associated with lowered scores (beta = -0.051rho= 0.04). Lipophilic statin therapy had non-significant protective effects over Clinical Dementia Rating sum-of boxes score variations only for APOE4- carriers. APOE4- haplotypes might enhance lipid availability to protect neuronal membranes, thus overcoming their supposed dysfunction in cholesterol metabolism, while APOE4+ carriers have inefficient neural repair mechanisms. In conclusion, APOE haplotypes seem to influence the protective effects of lipid profile variations for patients with Alzheimer's disease dementia, but current evidence is insufficient to propose lipid-lowering drugs as specific anti-dementia therapy. (C) 2017 Elsevier B.V. All rights reserved.
CitationNeuroscience Letters. Clare, v. 646, p. 36-42, 2017.
SponsorshipCAPES - Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
FAPESP - The State of Sao Paulo Research Foundation
- EPM - Artigos